[1] Turco L, Garcia-Tsao G. Portal hypertension: Pathogenesis and diagnosis. Clin Liver Dis,2019,23(4):573-587. [2] 周慧,冯晓宁,任浩,等.非肝硬化门脉高压患者临床特点分析. 实用肝脏病杂志. 2021,24(3): 415-418. [3] Khanna R, Sarin SK. Noncirrhotic portal hypertension: Current and emerging perspectives. Clin Liver Dis, 2019,23(4):781-807. [4] Alsomali MI, Yearsley MM, Levin DM, et al.Diagnosis of congenital hepatic fibrosis in adulthood. Am J Clin Pathol, 2020,153(1):119-125. [5] 何福亮,齐瑞兆,张珂,等. 脾切除联合贲门周围血管离断术治疗特发性非硬化性门脉高压所致食管胃底静脉曲张破裂出血的疗效分析. 临床和实验医学杂志,2020,19(13): 1402-1406. [6] Guido M, Alves VAF, Balabaud C, et al. International Liver Pathology Study Group. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology,2019,74(2): 219-226. [7] Zhuge Y, Liu Y, Xie W, et al. Chinese Society of Gastroenterology Committee of Hepatobiliary Disease. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol, 2019,34(4):634-642. [8] Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant, 2019,25(7):1271-1280. [9] Chan SS, Colecchia A, Duarte RF, et al. Imaging in hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant, 2020,26(10):1770-1779. [10] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京). 临床肝胆病杂志, 2017,33(9): 1627-1637. [11] 朱广昌,汪忠镐,卞策,等.布加综合征诊断与治疗的发展历程. 中国血管外科杂志(电子版),2017,9(1):4-10. [12] Qi X, Guo X, Fan D. Difference in Budd-Chiari syndrome between the west and China. Hepatology,2015,62(2):656. [13] Iliescu L, Toma L, Mercan-Stanciu A, et al. Budd-Chiari syndrome - various etiologies and imagistic findings. A pictorial review. Med Ultrason, 2019,21(3):344-348. [14] 中国医师协会腔内血管学专业委员会腔静脉阻塞专家委员会. 布-加综合征亚型分型的专家共识. 临床肝胆病杂志,2017,33(7):1229-1235. [15] 何福亮,王磊,赵洪伟,等.直接性肝内门腔分流术在布加综合征中的应用. 中华肝胆外科杂志,中华肝胆外科杂志,2021,27(1): 30-35. |